Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Summary

The purpose of this study is to determine the antitumor efficacy and safety of bendamustine (SyB L-0501: 90 mg/m\^2/day) for a maximum of 6 cycles (1 cycle: intravenous administration for 2 consecutive days and 26-day observation period) in patients with relapsed/refractory multiple myeloma.

Timeline

Start

2011-11

Primary completion

2013-07

Completion

2013-07

Drugs

Indications